Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancerArielle J. Medford, Aditya Bardia, Taronish D. Dubash et al.|npj Precision Oncology|2019Cited by 30
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast CancerNeelima Vidula, Aditya Bardia, Taronish D. Dubash et al.|Clinical Cancer Research|2020Cited by 24
A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O. Brett, Seth A. Wander, Taronish D. Dubash et al.|JCO Precision Oncology|2023Cited by 16
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Rachel O. Abelman, Aditya Bardia, Adrienne G. Waks et al.|Journal of Clinical Oncology|2024Cited by 6
Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclibJamie O. Brett, Seth A. Wander, Taronish D. Dubash et al.|Cancer Research|2022Cited by 1